Interchange Capital Partners LLC Acquires New Holdings in Eli Lilly and Company (NYSE:LLY)

Interchange Capital Partners LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 600 shares of the company’s stock, valued at approximately $281,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Guyasuta Investment Advisors Inc. grew its stake in Eli Lilly and Company by 4.6% in the second quarter. Guyasuta Investment Advisors Inc. now owns 3,024 shares of the company’s stock valued at $1,418,000 after purchasing an additional 132 shares in the last quarter. Banco Bilbao Vizcaya Argentaria S.A. grew its stake in shares of Eli Lilly and Company by 4.8% in the first quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 82,966 shares of the company’s stock valued at $28,449,000 after buying an additional 3,768 shares in the last quarter. Baystate Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 688.2% in the second quarter. Baystate Wealth Management LLC now owns 3,736 shares of the company’s stock valued at $1,752,000 after buying an additional 3,262 shares in the last quarter. Simon Quick Advisors LLC increased its holdings in Eli Lilly and Company by 13.0% during the second quarter. Simon Quick Advisors LLC now owns 1,874 shares of the company’s stock worth $879,000 after buying an additional 215 shares during the last quarter. Finally, Martin Capital Partners LLC bought a new stake in Eli Lilly and Company during the second quarter worth $234,000. 81.38% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on LLY shares. The Goldman Sachs Group lifted their price objective on shares of Eli Lilly and Company from $385.00 to $470.00 and gave the company a “neutral” rating in a research report on Wednesday, August 9th. Argus lifted their target price on Eli Lilly and Company from $470.00 to $620.00 and gave the stock a “buy” rating in a research note on Tuesday, September 5th. Barclays increased their price target on Eli Lilly and Company from $500.00 to $590.00 and gave the company an “overweight” rating in a research note on Wednesday, August 9th. HSBC initiated coverage on shares of Eli Lilly and Company in a research report on Friday, July 14th. They set a “buy” rating and a $560.00 price objective for the company. Finally, Royal Bank of Canada increased their price objective on shares of Eli Lilly and Company from $490.00 to $580.00 and gave the company an “outperform” rating in a research report on Tuesday, August 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and twenty have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $557.00.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Alonzo Weems sold 1,148 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total transaction of $678,445.04. Following the transaction, the executive vice president now directly owns 7,760 shares in the company, valued at approximately $4,586,004.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, major shareholder Lilly Endowment Inc sold 37,660 shares of the company’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $546,751.75, for a total transaction of $20,590,670,905.00. Following the transaction, the insider now owns 100,275,279 shares in the company, valued at $54,825,684,274,988.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Alonzo Weems sold 1,148 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total value of $678,445.04. Following the completion of the sale, the executive vice president now owns 7,760 shares of the company’s stock, valued at $4,586,004.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 700,916 shares of company stock valued at $20,970,455,882. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Up 3.2 %

NYSE:LLY opened at $619.13 on Thursday. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.05 and a quick ratio of 0.82. Eli Lilly and Company has a one year low of $309.20 and a one year high of $629.97. The company has a market cap of $587.75 billion, a PE ratio of 86.16, a P/E/G ratio of 3.74 and a beta of 0.33. The firm’s 50 day simple moving average is $573.25 and its 200 day simple moving average is $499.32.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, August 8th. The company reported $2.11 EPS for the quarter, beating the consensus estimate of $1.98 by $0.13. The business had revenue of $8.31 billion for the quarter, compared to analysts’ expectations of $7.58 billion. Eli Lilly and Company had a return on equity of 48.12% and a net margin of 15.55%. The firm’s revenue was up 28.1% on a year-over-year basis. During the same period in the prior year, the business posted $1.25 earnings per share. On average, research analysts anticipate that Eli Lilly and Company will post 6.65 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 0.73%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and Company’s dividend payout ratio is presently 62.87%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.